Claim­ing his­toric first, As­traZeneca says En­her­tu aces PhI­II for hard-to-reach seg­ment of pa­tients

As­traZeneca has racked up a cru­cial Phase III win for its megablock­buster prospect En­her­tu — one that could push the drug to un­char­tered places cur­rent­ly un­reach­able …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER